Recalcitrant dermatophytoses are on the rise and recent publications have documented high 25 minimum inhibitory concentrations (MICs) to TRB and squalene epoxidase (SQLE) mutations. 26 Biosystems). The amino acid sequence of SQLEp of all the investigated T. interdigitale in the 131 present study was compared with reference sequence of T. interdigitale (GenBank accession 132 number EZF33561). 133
However, literature correlating the laboratory the data with clinical response is lacking. 27
This study was conducted to study the clinico-mycological profile of tinea corporis and cruris, 28 including antifungal susceptibility testing (AFST) and SQLE mutation analysis and correlate 29 these with clinical response to TRB. Skin scrapings of patients with tinea corporis with/without 30 tinea cruris were subjected to species identification, AFST and SQLE gene analysis (on 15 31 isolates). KOH confirmed cases were started on TRB 250mg once a day (OD). If >50% clinical 32 clearance was achieved by 3 weeks; the same dose was continued.(Group 1). If clinical clearance 33 at 3 weeks was <50%, the dose was increased to 250mg twice a day (BD) (Group 2). If the 34 response still remained below 50% after 3 weeks of BD, the patients were treated with 35 itraconazole (ITR)(Group 3). Trichophyton interdigitale was confirmed on all 64 isolates 36 obtained on culture. Forty four (68.7%) isolates had high (≥1 µg/ml) MICs to TRB. Six isolates 37 were found to have aminoacid substitution Leu393Phe in SQLE protein, while one had the 38 substitution Phe397Leu. The difference in modal MICs to TRB between the 3 clinical response 39 groups (1.5157µg/ml, 5.0396 µg/ml and 20.1587µg/ml respectively for group 1,2 and 3) was 40 highly significant. Clinical response was achieved in 68% of those resistant by MIC data, and 41 42.8% of SQLE mutation harboring isolates, by increasing drug (TRB) exposure. 42
We infer that TRB resistance in dermatophytes has reached alarming proportions in our patients. 43
Though improved outcomes were achieved with higher drug exposure, with the high failure rate 44 seen in the study, the case for shifting to another class of antifungals as first line agent against 45 dermatophytoses is strong. 46
INTRODUCTION 47
Dermatophytoses of skin have been successfully managed with terbinafine (TRB) in the past. 48
The standard recommendation for tinea corporis/cruris has been TRB 250mg OD for 2-3 weeks; 49 and in fact even lesser treatment durations have been reported to be successful. (1-3) Of late 50 though, there has been an upsurge in difficult to treat dermatophytoses and declining responses 51 to TRB have been on record.(4-7) High minimum inhibitory concentrations (MICs) and 52 mutations in the target enzyme SQLE have been demonstrated in a few recent reports and the use 53 of higher TRB dosages is becoming common.(6,8-13) However, clinical breakpoints have not 54 been defined for TRB in dermatophytoses and the in vitro data cannot be directly applied to 55 clinical situations. 56
With this work, we aimed to study the clinico-mycological profile of our patients with 57 corporis/cruris and correlate the clinical response achieved with the standard treatment and 58 higher dose/durations of TRB with the MICs obtained in laboratory and with target gene (SQLE) 59 mutations. We also analysed the response of TRB failures to ITR. 60
PATIENTS AND METHODS (11) 61
The study was approved by the institutional ethics committee and registered with the clinical 62 trials registry of India (CTRI). The presented patients were recruited between July 2016 to 63 December 2017. Eighty five consecutive patients of tinea corporis, with or without tinea cruris, 64 presenting to the dermatology out patients department of Dr Ram Manohar Lohia hospital were 65 included after obtaining an informed consent. Those with co-existent tinea manuum/pedis/capitis 66 or tinea unguium were excluded. Diagnosis was made on clinical examination and confirmed by 67 KOH microscopy. The included patients had at least 5 lesions over the glabrous skin and/or large 68 lesion/s covering significant body surface area, and judged by the primary investigator (AK) as 69 4 requiring systemic treatment. Patients who had used any systemic anti-fungal in the preceding 4 70 weeks or used any topical antifungal or steroid in the preceding 2 weeks were excluded. Pregnant 71 or lactating women and children less than 12 years of age and/or weighing less than 40 kg were 72 also excluded. A detailed history of disease onset, duration, course, family history and previous 73 treatments was taken followed by examination of the entire skin surface to look for lesions. 74
Photographs (with Canon Powershot G12) were taken for documentation and comparison of 75 treatment response. The scales collected were transported to the Medical Mycology laboratory of 76
Vallabhbhai Patel Chest Institute, Delhi, in a thick dry sheet of paper. Treatment was started after 77 sending the samples and with KOH confirmation. Complete cure was defined as complete 78 clinical clearance along with a negative KOH from the site of initial sampling. 79
The patients were started on terbinafine in a dosage of 250 mg OD and asked to follow up 3 80 weekly. The treatment response was judged by the primary investigator at each visit by clinical 81 examination (based on extent of lesions, erythema and scaling) and comparison with previous 82 photographs. If the response to this regimen was greater than 50% at the 3 week follow up, the 83 same dose was continued till complete cure (Group 1). If the clinical response after 3 weeks was 84 less than 50% or if new lesions appeared during this time, the patient was shifted to terbinafine 85 250mg BD, and reassessed after another 3 weeks. If >50% clinical clearance was achieved by 86 this point, the same regimen was continued till complete cure (Group 2). However, if the 87 response still remained below 50%/new lesions appeared, the patient was shifted to ITR given in 88 a dose of 100mg BD and treated till complete cure. (Group 3) We chose a cutoff of 3 weeks as 89 this has been the standard recommended treatment duration for tinea corporis/cruris. (1, 14) The 90 patients were counseled on general hygiene measures and ways to reduce transmission among 91 family members. No topical antifungal was given to avoid additive effect and patients were 92 5 instructed to use only emollients topically. Antihistamines were prescribed as per the patient's 93 symptoms. Patients were asked of adverse effects pertaining to TRB at each visit and liver 94 function tests were performed periodically. 95
Skin scrapings were processed for direct microscopic examination by 10% potassium hydroxide 96 (KOH)/Blankophor. The specimens were inoculated on two sets each of Sabourauds dextrose 97 agar (SDA) containing gentamicin and chloramphenicol and the other containing cycloheximide 98 (0.05%) incubated at 28°C for 2 weeks. Preliminary macroscopic phenotypic identification was 99 done on potato dextrose agar (PDA) incubated at 28°C for 14 days. Slide cultures prepared on 100 PDA and mounted in lactophenol cotton blue were examined microscopically. The amplification primers for SQLE gene, as described previously were used. 10 PCR was carried 124 out in a 50 μL reaction volume and the conditions included initial denaturation for 5 minutes at 125 95°C followed by 34 cycles of 30 seconds at 95°C, 30 seconds at 60°C and 180 seconds at72°C. 126 DNA sequencing was performed using the PCR primers at2.5 mmol/L concentration. All 127 sequencing reactions were carried out in a 10 μL reaction volume using BigDye Terminator Kit 128 v3.1(Applied Biosystems, Foster City, CA, USA) according to the 129 manufacturer'srecommendations and analysed on an ABI3130xL GeneticAnalyzer (Applied 130 7 A total of 85 patients were included. Of these, 64 samples (75.3%) could be grown on culture 138 and were taken up for further analysis. Out of these 64 culture positive patients, there were 44 139 males and 20 females. Ages of patients ranged from 14 to 71 years, with a mean age of 34.9 140 years. Disease duration ranged between 3 weeks to 5 years, with an average duration of 8.8 141 months. Thirty five (54.6%) patients had a positive family history of dermatophytic infections, 142 either at present or in recent past. Interestingly, 45 patients gave a history of sharing of towels 143 between family members, bringing out the importance of fomite transmission in households. 144
Only 2 had pets at home and those were apparently uninfected as per the patients' account. Eight 145 were involved in regular outdoor sports activities and 37 gave history of prolonged working in 146 hot and humid conditions, either at home or as a part of their vocation. 147
Most patients (51) gave a visual analogue score (VAS) between 8 to 10 for associated pruritus. 148
Forty five (70.3%) patients had a history of application of topical steroid creams, either plain 149 steroid or as a combination with antifungals. The most commonly used topical steroid was 150 clobetasol (27) followed by betamethasone (17), beclomethasone (5), fluticasone (2) and 151 mometasone (2). Seven had used more than one class of topical steroid. Most (32; 71.1%) had 152 procured these over the counter from pharmacists without a prescription, while the rest (13, 153
28.8%) were prescribed by general practitioners. Nine had apparent signs of topical steroid abuse 154 in the form of striae, skin thinning and depigmentation. Three of the patients were diabetics on 155 treatment, while one each had coronary artery disease and iron deficiency anemia. 156 Most patients (30; 46.8%) had 5-10 lesions at presentation, while 16 (25%) had 10-20, 13 157 (20.3%) had more than 20 and 5(7.8%) had 5 or less lesions. Among the culture positive patients, complete follow up data was available for 30 patients and 169 these were further included for the clinico-mycological correlation. (Table 2 ) Fifteen (50%) out 170 of these responded to prolonged duration of OD TRB, given beyond 3 weeks in all but 2 patients. 171
The mean duration of response in this group was 39.46±13.12 days (range 21-66 days). Out of 172 these 15, 8 had MIC of 1µg/ml, 2 had MIC of 0.5 µg/ml, 1 each had MIC of 0.25µg/ml,2µg/ml 173 and 4µg/ml and 2 had MIC of ≥32µg/ml. The GM MICs to TRB in this group was 1.515µg/ml. 174
Only one patient in this group had history of previous terbinafine exposure, while 10 (66.67%) 175 had applied topical steroids over their lesions previously. 176
The other 15 patients did not show a clinically relevant response (>50% clearance) to OD TRB 177 till 3 weeks and were shifted to BD dosing. Six of these showed >50% clearance after 3 weeks of 178 updosing and were continued on this dose till complete cure. The TRB MIC distribution in this 179 group was 1µg/ml in 2, ≥32µg/ml in 3 patients and 0.5µg/ml in 1. The GM MIC for the group 180 was 5.039µg/ml and average duration of treatment (including OD and BD treatment) was 181 9 55.66±20.48 days (range 42-86 days). Only one patient in this group had used terbinafine 182 previously, while 5 had applied topical steroids previously. 183
Finally, 9 patients did not achieve 50% clinical clearance even after 6 weeks of TRB (3 weeks of 184 OD and 3 weeks of BD) and were treated with itraconazole(ITR) 100 mg BD for duration 185 ranging from 21 to 51 days (mean 31.88±3.64 days). Eight of these had TRB MICs of ≥32µg/ml, 186 while one had MIC of 0.5µg/ml. The GM MIC to TRB was 20.158µg/ml. Seven of these had 187 been treated with TRB previously (2 with oral TRB, 3 with topical TRB and 2 with both oral and 188 topical TRB) and 7 had applied topical steroids previously. MICs to ITR in the 9 patients ranged 189 from 0.125 to 1µg/ml, with GM MIC of 0.314µg/ml. 190
The difference between the GM MICs between the three groups was highly significant 191 (p=0.004), as was the difference between GM MICs of combined group 1 and 2 (patients who 192 achieved cured with TRB, with any dose/duration; 2.136µg/ml) and group 3 (who were not cured 193 even with higher drug exposure; 20.159µg/ml) (p=0.004). However, we didnot find a statistically 194 significant correlation between individual MICs or susceptibility based on MIC (MIC≥1 µg/ml 195 or <1 µg/ml) with cure achieved with TRB (with standard or higher drug exposure). We also did 196 not find any significant association between cure achieved with TRB or MIC values to TRB with 197 family history of tinea, duration of the disease, past history of topical steroid use or history of 198 episodes of tinea in recent past. 199
Among those infected with TRB susceptible organisms (MIC<1 µg/ml), 80% achieved cure, 200 while 68% of those infected with resistant organisms achieved cure, either by standard 201 dose/duration of treatment or by updosing/increasing treatment duration. (Table 3) The odds of 202 achieving cure with TRB, when infected with a susceptible organism were 1.88 times the odds of 203 achieving cure when the organism was TRB resistant. Further, of the 4 susceptible TRB 204 10 responsive patients, one achieved cure with standard dose and duration of TRB, 2 to longer 205 duration of the standard dose and 1 after updosing to BD. Of those infected with resistant 206 organism, most of those who responded (11), responded with an increase in the treatment 207 duration of OD dose, while 5 achieved cure with updosing. 208
Squalene epoxidase (SQLE) gene mutation analysis was done in a total of 15 (out of 64) isolates. 209
Out of these, 7 harbored mutations leading to single amino acid substitution in the SQLE protein. 210 (TABLE 2) The MICs in mutated isolates were 4 µg/ml (1 isolate) and >32 µg/ml (6 isolates)The 211 8 isolates which did not demonstrate mutations had MICs of 0.5 µg/ml (5) and 1 µg/ml (3) .Six 212 of the mutation harboring isolates had the aminoacid substitution Leu393Phe in SQLE protein 213 and one had the substitution Phe397Leu. Four of these belonged to treatment group 3, 1 to group 214 2 and 2 to group 1. Four (57.1%) of these patients had previous exposure to TRB (oral/topical). 215
Three patients (42.8%) with SQLE mutations responded to higher dose/longer duration of 216 treatment, while 4 (57.14%) did not respond to the drug even after increasing the drug exposure. 217
DISCUSSION 218
A predominant finding of our study is the very high level (68.7%) of TER resistance in our 219 isolates. Secondly, correlation of the clinical response to TRB with mycological parameters of 220 MIC and SQLE gene mutations revealed that increasing TRB drug exposure is able to achieve 221 cure in about 68% of isolates resistant by MIC data and about 57% of confirmed SQLE mutated 222 isolates' infections. The data we have presented here forms the basis of establishing clinical 223 breakpoints for a drug-species pair, although larger patient numbers and intricate tissue level PK 224 data would also be essential for the same. The rest in group 1 required much longer courses ranging from 28 to 66 days. Notably, all but 3 274 of the group 1 patients had MICs of 1µg/ml or more, but responded to longer courses of the drug. 275
Extrapolating from the data on azoles, it is known that optimizing drug exposures can improve 276 clinical outcomes in the wake of raised MICs/resistant strains, depending on the variables like 277 the degree of rise in MICs, resistance mechanism and pharmacokinetic/pharmacodynamics 278 (PK/PD) properties of the antifungal agent. can be interpreted that longer courses lead to higher levels of TRB in the SC. The authors 282 reported SC levels of 14.4µg/g after administration of TRB 250mg OD for 28 days vs 7.63µg/g 283 at the end of a 14 day course and 2.52µg/g at the end of a 7 day course of the same dose.(37-38) 284
The higher levels thus achieved with longer durations may have been able to surmount the higher 285 MICs in group 1 patients. 286
Further, on updosing to BD, another 6 patients achieved complete cure. As defined in previously 287 done PK studies, TRB has a linear PK profile upto750mg of dose, implying that an increase in 288 dose till this level would increase plasma levels proportionately.(39) And this would in all 289 likelihood lead to an increased SC level, unless the uptake by skin is saturable, of which there is 290
no documentation yet to the best of our knowledge. This group benefitted both from an increase 291 in dose and an increase in duration, possibly achieving higher SC levels than achieved by group 292 1. Notably, the GM MIC of group 2(5.039µg/ml) was about 5 times higher than that of group1 293 (1.5157µg/ml). This may explain why the group 2 patients did not respond only with longer 294 durations of treatment. 295 14 Finally 9 patients did not achieve 50% clinical clearance even after 6 weeks of TRB (OD for 3 296 weeks followed by BD for 3 weeks) and were then treated with itraconazole. The GM MIC of 297 this group was 20.159µg/ml, which was about 20 times that of group 1 and 4 times that of group 298 2. This demonstrates a trend wherein higher drug exposure surmounts the higher MICs to an 299 extent, after which the drug fails to work. Whether doses higher than what we used would 300 improve cure rates further may be an area of further research, though further increases may be 301 limited by drug toxicity. We did not observe any drug related adverse effects with using longer 302 durations and higher doses of TRB, although the data may be biased by a small sample size.(40) 303
Analyzing the clinical response data of the 7 patients in whom SQLE mutations were 304 characterized, 4 of these (57.1%) did not respond to higher drug exposure, while 3 (42.8%) did. 305
This data, though small, largely supports the 90-60 rule of clinical correlation with invitro 306 susceptibility testing, wherein about 60% of resistant isolates respond to the drug in vivo.(41) 307
The susceptibility based on MIC data also gives a similar interpretation, wherein 68% of the 308 isolates with MIC≥1 µg/ml could be successfully treated with TRB. One of these (patient 3) 309 responded to the usual dose and duration of TRB, while the other 16 required longer 310 durations/higher dose. In both the present study and our previous work, SQLE mutations were 311 noted in isolates with MICs 4 to ≥32 μg/mL and wild type genotype (i.e., no SQLE mutation) 312 was noted in T. interdigitale isolates with MICs ≤2 μg/mL This may imply that SQLE mutations 313 lead to a high level resistance inT. interdigitale and alternate mechanisms may be working in 314 resistant isolates with MICs <4 μg/mL.(11) 315
We couldnot identify any host factors predisposing to TRB resistance. Topical steroid use may 316 enhance development of resistance to antifungals being used simultaneously, by activating 317 fungal metabolism and by a cell membrane protective activity. However, we did not find a 318 15 statistically significant correlation between topical steroid use and clinical response to TRB. One 319 possible reason for this could have been the widely prevalent use of topical steroids in our 320 patients which precluded formation of comparable groups. Indeed, 21 of the 30 analyzed patients 321 had used topical steroids before, while only 9 had not. Prior TRB exposure also did not yield any 322 predictable results although on general observation of the trend among the 3 treatment groups, 323
we observed previous TRB exposure to be most prominent in group 3 (77.78% in group 3 vs 324 6.67% in group 1 and 16.67% in group 2). Age, family history of tinea and history of recurrent 325 tinea in the past also had no significant correlation with TRB resistance (based on MIC values). 326
Whether the resistance we have seen was primary or acquired cannot be commented upon a 327 single time assessment. But it was an interesting finding that most (16/17; 94.11%) of those who 328 were resistant and yet responded to TRB had not been exposed to TRB before, while most of 329 those who were resistant and did not respond to TRB (7/8; 87.5%) had been exposed to TRB 330 before. 331
All 9 patients who failed TRB were successfully treated with ITR. These all were sensitive to 332 ITR based on MIC data as well. Overall too, ITR resistance was seen in only one of the 64 333 isolates. Thus, ITR sensitivity seems to be preserved in dermatophytes so far, and ITR may 334 become a frontline drug for dermatophytoses with rising failures being seen with TRB. 335
In the end, we would like to highlight that resistance to TRB has reached a worrisome level in 336 isolates from dermatophyte infections in our patients. Increasing drug exposure by means of 337 higher dose/duration can surmount this to some degree, but the high failure rate still (30%) 338 cannot be ignored. Although localized to a few geographical locales so far, it may not be long 339 before the resistance spreads to other regions and it would be desirable to preplan strategies to 340 16 combat the same. A rethink on the treatment order and development of newer drug classes 341 against dermatophytes with novel mechanisms of action is due. 342 
